Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.

@article{Custodio2009PrognosticAP,
  title={Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.},
  author={Ana Bel{\'e}n Custodio and Jos{\'e} Lu{\'i}s Gonz{\'a}lez-Larriba and Jana Bobokova and Antonio Calles and R {\'A}lvarez and Eugenio Cuadrado and Ar{\'a}nzazu Manzano and Eduardo Diaz-Rubio},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2009},
  volume={4 7},
  pages={891-910}
}
Lung cancer-predominantly non-small cell lung cancer (NSCLC)-is the leading cause of death from cancer in most industrialized countries. Patients with early-stage NSCLC are at substantial risk for recurrence and death even after potentially curative surgery. Multiple large randomized trials have demonstrated that adjuvant chemotherapy using modern cisplatin-based regimens can significantly improve 5-year survival in carefully selected patients with NSCLC.The current staging system is inadequate… CONTINUE READING